# Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk

> **NCT07347977** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Ningbo University** · enrollment: 1400 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Recurrence
- Survival Analysis

## Interventions

- **DRUG:** Lidocaine (drug)

## Key facts

- **NCT ID:** NCT07347977
- **Lead sponsor:** First Affiliated Hospital of Ningbo University
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347977, "Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07347977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*